Clinical trial · Interventional
Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies
Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies in Prostate Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Difficulties encountered in enrolling patients
Summary
Brief summary (as posted)
Prostate cancer is the first cancer in humans (25%). The most widely used tracer in oncology, the 18-Fluoro DeoxyGlucose does not allow the study of prostatic neoplasia. On the other hand, Choline, which is an amino alcohol, is involved in the synthesis of cell membranes and has an affinity for prostate cells. Its concentration is directly proportional to cell proliferation. The analogue of choline has the advantage of having a rapid and stable accumulation over time in cancer cells, with a rapid urinary excretion (4 minutes after injection). The goal of this study is to assess the feasibility and the accuracy for targeting image guided prostate biopsy to detect prostate cancer after Imaging fusion of choline-PET/CT compared to 1.5T multiparametric magnetic resonance imaging (mpMRI) with 3D-transrectal ultrasound (TRUS) .
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fluorocholine | — | UNRESOLVED | — |
| Positron-Emission Tomography | — | UNRESOLVED | — |
| Prostatic Neoplasm | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| mpMRI | Device | — | UNRESOLVED |
| PET Scan ou TEP-TDM | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Prostate cancer/TEP scan
- interventionNames
- Device: PET Scan ou TEP-TDM
- type
- ACTIVE_COMPARATOR
- label
- Prostate cancer/mpMRI
- interventionNames
- Device: mpMRI
Primary outcomes (1)
- measure
- Number of image guided prostate biopsy in the zones detected by the TEP scan
- timeFrame
- at inclusion
Secondary outcomes (1)
- measure
- Number of image guided prostate biopsy in the zones detected by the mpMRI
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with suspicion of prostate cancer * Patients who performed prostate mpMRI and F-Choline 18 PET scan * Patient capable of receiving clear informations * Patient giving a written consent for their participation via a consent signed by both parents of the patient (or legal tutor) * Patient covered by a healthcare insurance Exclusion Criteria: * Patients without suspect image of neoplasia after mpMRI and F-Choline 18 PET scan
References
Publications (0)
Data not yet available